Anafranil is a prescription medicine for people with obsessive-compulsive disorder and selected depressive or anxiety-related conditions. Its active ingredient, clomipramine, changes serotonin and noradrenaline signalling in the central nervous system to help reduce relevant symptoms.
Anafranil is a prescription tablet containing clomipramine, a tricyclic antidepressant used mainly for obsessive-compulsive disorder. It may also be selected for certain depressive or anxiety-related conditions when a clinician considers its benefits and risks appropriate. Clomipramine changes serotonin and noradrenaline signalling in the central nervous system.
Anafranil contains clomipramine hydrochloride, also written as clomipramine HCl. It belongs to the tricyclic antidepressant group and acts within the central nervous system, or CNS. The active ingredient produces the therapeutic effects; inactive tablet components support the tablet’s shape, stability, and administration.
Clomipramine is sometimes described as a tertiary tricyclic or heterocyclic antidepressant. These terms describe its chemical and pharmacological family. They do not determine whether the medicine is suitable for a specific person.
Clomipramine is the generic name associated with Anafranil. Clomipramine hydrochloride is the salt form used in the medicine. A prescription may therefore refer to Anafranil, clomipramine, or clomipramine HCl.
The tablet strength is selected by the prescriber. It should not be interpreted as an individual dosing recommendation.
Tricyclic antidepressants influence several neurotransmitter systems. Neurotransmitters are chemical messengers that help nerve cells communicate. Clomipramine has a strong effect on serotonin reuptake and also influences noradrenaline signalling.
This broad activity helps explain both its clinical effects and its side-effect profile. Dry mouth, constipation, blurred vision, drowsiness, dizziness, and changes in heart rhythm can occur because tricyclic medicines affect more than one receptor system.
Anafranil is supplied as tablets. Clomipramine tablet strengths and release formulations can differ between markets and prescriptions. The prescriber chooses the strength and schedule according to the condition being treated, age, response, medical history, and tolerability.
The prescribed dose is not interchangeable between immediate-release and modified-release formulations. Tablets should be taken exactly as directed.
Clomipramine is often introduced cautiously and adjusted according to response and side effects. Older adults may be more sensitive to dizziness, confusion, constipation, urinary retention, and heart-rate changes. Children and adolescents require specialist assessment.
A dose that helped one person may cause excessive sedation or cardiovascular effects in another. Do not use someone else’s prescription or transfer tablets between family members.
Clomipramine reduces the reuptake of serotonin in the CNS and also affects noradrenaline reuptake. Reuptake is the process by which nerve cells remove neurotransmitters from the space between them. Reducing this process allows signalling to remain active for longer.
The FDA prescribing information describes clomipramine as a tricyclic compound with effects on serotonin and noradrenaline transmission [1]. These effects help explain why the medicine can influence obsessions, compulsions, mood, anxiety, and certain sleep-related symptoms.
Serotonin and noradrenaline are neurotransmitters involved in mood, anxiety, attention, arousal, and other brain functions. Mental health conditions cannot be explained by a single neurotransmitter level. Clomipramine’s action is broader than simply replacing a missing chemical.
The medicine also blocks muscarinic, histamine, and alpha-adrenergic receptors to varying degrees. Those secondary actions contribute to dry mouth, constipation, sedation, dizziness, blurred vision, and postural blood-pressure changes.
Anafranil is used mainly in the treatment of obsessive-compulsive disorder, or OCD. OCD involves recurring intrusive thoughts, urges, or images and repetitive behaviours or mental acts performed to reduce distress. Clomipramine can reduce the intensity and frequency of these symptoms for some patients.
It may also be prescribed for selected depressive symptoms, panic attacks, phobias, or other anxiety-related presentations. These uses depend on the clinical diagnosis, local prescribing practice, previous treatment response, and the prescriber’s assessment.
| Clinical use | Main treatment target | Clinical context |
|---|---|---|
| OCD | Obsessions and compulsions | Often combined with psychological treatment |
| Depression or anxiety symptoms | Persistent mood or anxiety symptoms | Treatment choice depends on history and tolerability |
| Narcolepsy-related symptoms | Selected sleep-related symptoms | Requires assessment by a sleep specialist |
For OCD, medication is only one part of treatment planning. Exposure and response prevention, a structured form of cognitive behavioural therapy, is an established psychological treatment. It helps a person face feared thoughts or situations without performing the usual compulsive response.
A gradual response is expected. Early drowsiness or dry mouth does not prove that OCD symptoms will improve, and symptom relief may take time after the dose has been adjusted.
Older references may use the term endogenous depression for depressive illness without an obvious external trigger. Current assessment focuses on the person’s symptoms, duration, functional impairment, medical history, and suicide risk rather than relying on that older label.
Anafranil is not automatically the first treatment for every depressive or anxiety condition. A clinician may consider previous antidepressant response, coexisting heart disease, seizure risk, sleep problems, other medicines, and the patient’s tolerance of anticholinergic effects.
Clomipramine has been used in selected cases to reduce symptoms such as cataplexy associated with narcolepsy. It does not correct the underlying sleep disorder. Diagnosis and treatment planning should involve a sleep specialist when narcolepsy is suspected.
Treatment selection for OCD or depression depends on the diagnosis, previous response, coexisting illness, interactions, and side-effect priorities. Clomipramine can be useful for OCD, yet it often carries more anticholinergic and cardiac tolerability concerns than many selective serotonin reuptake inhibitors.
| Treatment approach | Main role | Main limitation |
|---|---|---|
| Clomipramine | Medication option for OCD and selected conditions | Dry mouth, constipation, sedation, and cardiac risks |
| SSRI category | Common medication approach for OCD or depression | Sexual dysfunction, gastrointestinal effects, withdrawal symptoms |
| Psychological therapy | Exposure and response prevention for OCD; structured therapy for depression | Requires access, regular participation, and time |
Switching between clomipramine and an SSRI may require tapering, a washout period, or specialist supervision. The correct approach depends on the medicines involved and the risk of withdrawal or serotonin toxicity.
Medication and psychological therapy can be used together. For OCD, exposure and response prevention targets the learned cycle of fear and compulsion, while medication may reduce symptom intensity enough to support therapy participation.
It is not for you if you have untreated narrow-angle glaucoma, a recent heart attack, or current treatment with a monoamine oxidase inhibitor.
Before treatment, tell the prescriber if you have mental health concerns, seizures, heart disease, blood-pressure problems, urinary symptoms, glaucoma, liver problems, thyroid disease, or pregnancy-related considerations. Also explain all medicines you take, including antidepressants, stimulants, opioids, sleep medicines, and migraine medicines.
Do not combine Anafranil with alcohol, sedatives, sleeping medicines, sedating antihistamines, or other antidepressants without medical advice. Seek urgent medical help for fainting, a fast or irregular heartbeat, severe confusion, a seizure, extreme agitation, high fever with muscle rigidity, severe eye pain with visual disturbance, inability to pass urine, or thoughts of self-harm.
Common effects include dry mouth, constipation, sweating, blurred vision, drowsiness, dizziness, tremor, headache, nausea, appetite changes, and sexual dysfunction. Effects can be dose-related. Some improve as the body adapts, while others require a change in treatment. Constipation and dry mouth are easy to underestimate. Persistent constipation can become painful, and severe dry mouth can affect teeth and swallowing.
Clomipramine should not be combined with monoamine oxidase inhibitors unless a specialist has planned the necessary treatment interval. Combining serotonergic medicines can increase the risk of serotonin toxicity.
Relevant interaction groups include:
The cardiac risk is more relevant for people with known heart disease, electrolyte disturbances, a history of fainting, or treatment with several rhythm-affecting medicines.
Dry mouth may improve with sugar-free gum or frequent small sips of water. Blurred vision can make reading and driving unsafe. Dizziness is more likely when standing quickly, especially during dose changes.
Sexual dysfunction can include reduced desire, delayed orgasm, or difficulty reaching orgasm. It should be reported plainly because treatment adjustments may be possible.
The most frequent errors involve dose changes, interactions, and misreading early effects.
Early follow-up is essential after starting treatment or changing the dose. Younger patients and people with previous suicidal thoughts may need closer monitoring during the initial period and after dose changes.
In clinical practice, prescribers often assess clomipramine by tracking both target symptoms and tolerability. For OCD, useful measures include time spent on compulsions, avoidance behaviour, distress from intrusive thoughts, sleep, and daily functioning.
A psychiatrist would usually explain that the medicine needs consistent use and planned follow-up. The first appointment after starting or changing treatment may focus more on adverse effects, agitation, sleep, blood pressure, pulse, and suicide risk than on final symptom improvement.
Patients sometimes stop treatment after a few uncomfortable days because drowsiness or dry mouth appears first. Others continue despite severe constipation, palpitations, or urinary difficulty because they expect every side effect to fade. Both patterns need review.
Anafranil is strongly associated with OCD treatment because clomipramine affects serotonin signalling involved in obsessive and compulsive symptoms. The FDA prescribing information from 2018 identifies obsessions and compulsions in OCD as the central indication . NICE guidance updated in 2022 also places medication and exposure and response prevention within OCD treatment planning [2].
The response develops gradually and varies by diagnosis, dose adjustment, treatment duration, and psychological support. Early side effects can appear before meaningful improvement, so a few uncomfortable days do not establish whether treatment will succeed. The WHO mhGAP Intervention Guide, published in 2019, supports planned follow-up for antidepressant treatment and monitoring of clinical response [3].
Sudden discontinuation can lead to withdrawal symptoms, sleep disturbance, nausea, irritability, sweating, headache, or a return of the treated symptoms. The FDA product information from 2018 supports gradual treatment changes when clinically appropriate rather than unsupervised abrupt cessation . The tapering plan depends on treatment duration, dose, formulation, and the person’s symptoms.
The combination can raise the risk of excessive serotonergic effects and may also alter clomipramine levels. A planned switch or combination requires prescriber supervision, with attention to treatment intervals, symptoms, heart rhythm, and other medicines. NICE guidance from 2022 treats medication selection for OCD as an individual clinical decision rather than a universal combination strategy .
Drowsiness, dizziness, and reduced alertness can occur because clomipramine affects histamine and other receptor systems in addition to serotonin and noradrenaline. The FDA label from 2018 advises caution with activities requiring mental alertness until the person knows the individual response . Alcohol, opioids, sleeping medicines, and sedating antihistamines may intensify these effects.
Urgent assessment is needed for a seizure, fainting, irregular heartbeat, severe confusion, high fever with muscle stiffness, severe agitation, or thoughts of self-harm. Serotonin toxicity may involve agitation, sweating, tremor, diarrhoea, fever, and muscle rigidity. WHO guidance from 2019 supports prompt escalation when serious mental-health or medicine-related warning signs appear .
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
After several weeks, I noticed that compulsive checking took less time and I could leave home more easily. The first days brought dry mouth and evening sleepiness, so I stopped driving until I knew how the tablets affected me.
My mood became steadier after the treatment had been adjusted. Constipation was the problem I underestimated. Adding fibre helped somewhat, but I still needed to discuss it at follow-up.
The intrusive thoughts did not disappear immediately, and the overall benefit was less than I had hoped. Therapy made a major difference because I learned to resist the rituals instead of waiting for the tablet to solve everything.
I felt dizzy when standing during the first part of treatment. The symptom improved after the prescriber reviewed the schedule, but I would not have changed the timing myself.
